An orally bioavailable broad-spectrum Hsp90 inhibitor (Hsp90i) therapy to suppress emerging Coronavirus (CoV) infections
Research Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Good Ventures Foundation
Start Date
May 1, 2020
End Date
June 30, 2021
Administered By
Duke Human Vaccine Institute
Awarded By
Good Ventures Foundation
Start Date
May 1, 2020
End Date
June 30, 2021